Oxiracetam

Modify Date: 2024-01-02 10:54:46

Oxiracetam Structure
Oxiracetam structure
 Common Name Oxiracetam
CAS Number 62613-82-5 Molecular Weight 158.155
Density 1.4±0.1 g/cm3 Boiling Point 494.6±40.0 °C at 760 mmHg
Molecular Formula C6H10N2O3 Melting Point 165-168ºC
MSDS Chinese USA Flash Point 252.9±27.3 °C
Symbol GHS07
GHS07		 Signal Word Warning

 Use of Oxiracetam


Oxiracetam is a cyclic derivative of γ-aminobutyric acid (GABA) which has been commonly used as nootropic drug to treat cognitive impairments.

 Names

Name 4-Hydroxy-2-Oxopyrrolidine-N-Acetamide
Synonym More Synonyms

 Oxiracetam Biological Activity

Description Oxiracetam is a cyclic derivative of γ-aminobutyric acid (GABA) which has been commonly used as nootropic drug to treat cognitive impairments.
Related Catalog
Target

GABA receptor[1]

References

[1]. Li W, et al. (S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates the Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats. Sci Rep. 2017 Aug 30;7(1):10052.

 Chemical & Physical Properties

Density 1.4±0.1 g/cm3
Boiling Point 494.6±40.0 °C at 760 mmHg
Melting Point 165-168ºC
Molecular Formula C6H10N2O3
Molecular Weight 158.155
Flash Point 252.9±27.3 °C
Exact Mass 158.069138
PSA 83.63000
LogP -2.48
Vapour Pressure 0.0±2.9 mmHg at 25°C
Index of Refraction 1.570
Storage condition 2-8°C

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
UX9656638
CHEMICAL NAME :
1-Pyrrolidineacetamide, 4-hydroxy-2-oxo-
CAS REGISTRY NUMBER :
62613-82-5
BEILSTEIN REFERENCE NO. :
1529719
LAST UPDATED :
199612
DATA ITEMS CITED :
8
MOLECULAR FORMULA :
C6-H10-N2-O3
MOLECULAR WEIGHT :
158.18

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 5,405,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 5,405,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 5,405,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 5,405,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 5,405,1980
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 5,405,1980 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
182 gm/kg/52W-C
TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 19,3519,1991 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
22 gm/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - delayed effects
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 19,3545,1991

 Safety Information

Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H315-H319
Precautionary Statements P305 + P351 + P338
Personal Protective Equipment dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes Xi
Risk Phrases R36/38
Safety Phrases S26-S36
RIDADR NONH for all modes of transport
WGK Germany 3
RTECS UX9656638
HS Code 2933790090

 Customs

HS Code 2933790090
Summary 2933790090. other lactams. VAT:17.0%. Tax rebate rate:9.0%. . MFN tariff:9.0%. General tariff:20.0%

 Articles27

More Articles
Minaprine, but not oxiracetam, prevents desipramine-induced impairment of avoidance learning in mice.

Pol. J. Pharmacol. 47(1) , 69-73, (1995)

The tricyclic antidepressant desipramine impaired shuttle-box avoidance acquisition in mice of the CD-1 strain. The nootropic drug oxiracetam was unable to prevent the desipramine-induced learning imp...

Pre- and postprandial pyridostigmine and oxiracetam effects on growth hormone secretion in anorexia nervosa.

Psychoneuroendocrinology 21(7) , 621-9, (1996)

Previous studies have shown that food ingestion is not capable of inhibiting the GHRH-induced GH release in anorexia nervosa, at variance with what is observed in normal subjects. Moreover, a choliner...

Putative cognition enhancers reverse kynurenic acid antagonism at hippocampal NMDA receptors.

Eur. J. Pharmacol. 272(2-3) , 203-9, (1995)

Oxiracetam, aniracetam and D-cycloserine, three putative cognition enhancers, were examined in a functional assay for NMDA receptors. Rat hippocampal slices or synaptosomes were labeled with [3H]norad...

 Synonyms

4-Hydroxy-2-oxopyrrolidine-N-acetamide
2-(4-Hydroxypyrrolidin-2-on-1-yl)acetamide
MFCD00242951
oxiracetam
1-Pyrrolidineacetamide, 4-hydroxy-2-oxo-
2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide
2-(4-Hydroxy-2-oxo-1-pyrrolidinyl)acetamide
UNII:P7U817352G
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Oxiracetam suppliers

Price: ￥148.2/1g

Reference only. check more Oxiracetam price

Related Compounds: More...
oxiracetam
88929-35-5
oxiracetam
68252-28-8
Oxiracetam-¹³C2,¹⁵N
1346602-09-2
Oxiracetam Impurity 5
120428-80-0
Oxiracetam Impurity 6
62833-66-3
Oxiracetam Impurity 2
106-57-0
Oxiracetam Impurity 1
7491-74-9
Oxiracetam Impurity 16
89490-41-5
Oxiracetam Impurity 10
10479-85-3
Ethyl 4-(2-((4-chlorobenzo[d]thiazol-2-yl)(methyl)amino)acetyl)piperazine-1-carboxylate
1396876-35-9
4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
1158522-08-7
1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
940364-43-2
2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
134104-43-1
1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
131615-57-1
(4-Methyl-tetrahydro-furan-2-yl)-methanol
6906-52-1
N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
930439-75-1
4,5,6,7-Tetrahydrobenzo[d]isoxazole-3-carbaldehyde
1018584-77-4
tert-Butyl-DL-alanine
1375289-11-4
4-amino-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-ethylbenzenesulfonamide
849349-65-1
Chemsrc provides Oxiracetam(CAS#:62613-82-5) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Oxiracetam are included as well.>> amp version: Oxiracetam

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved